Option Investor
Newsletter

New Position 1/18/05 8:30 PM EST

HAVING TROUBLE PRINTING?
Printer friendly version

MYGN - Myriad Genetics $25.88

Myriad Genetics (NASDAQ:MYGN) is a biopharmaceutical company

focused on the development of novel therapeutic products and

the development and marketing of predictive medicine products.

The company's researchers have made important discoveries in

the fields of cancer, Alzheimer's disease, viral diseases (such

as HIV), depression and obesity.

Myriad is currently conducting a human clinical trial to evaluate
Flurizan for the treatment of Alzheimer's disease. The trial is
designed to determine Flurizan's ability to alter the course of
cognitive decline and behavioral change in patients with
Alzheimer's disease.

Investors appear confident of the outcome, having pushed the
shares up $3.02, or 13.8 percent, to $24.95 in Tuesday's session.
MYGN was also one of the the biggest gainers on the Nasdaq.

Fundamentals: http://finance.yahoo.com/q/ks?s=MYGN&quicken=2

Chart: http://finance.yahoo.com/q/bc?s=MYGN&t=6m

Sell Put FEB 22.50 GSQ-NX
Bid = $0.45 Open Interest = 160
Potential Profit (5 contracts) = $225
Return on Investment (max) = 5.8%
Cost Basis in Stock = $22.05
Days to Expiration = 32

Option Writers Newsletter Archives